# Flaxseed Lignan Supplementation in Elderly Participants With Stage I Hypertension

Study · id `cardio:ct-nct02391779` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02391779](<https://clinicaltrials.gov/study/NCT02391779>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02391779

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 100 participants.

## Technical summary

Registry record NCT02391779. Randomized; double masking; primary purpose treatment. Start 2015-05 (registry gives no type); primary completion 2017-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT02391779, source copy `cardio:ctgov-nct02391779-2018-01-10`, retrieved 2026-10-26)
- Start date: 2015-05 (registry gives no type) (ClinicalTrials.gov record NCT02391779, source copy `cardio:ctgov-nct02391779-2018-01-10`, retrieved 2026-10-26)
- Primary completion: 2017-07 (actual) (ClinicalTrials.gov record NCT02391779, source copy `cardio:ctgov-nct02391779-2018-01-10`, retrieved 2026-10-26)
- Completion: 2017-07 (actual) (ClinicalTrials.gov record NCT02391779, source copy `cardio:ctgov-nct02391779-2018-01-10`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT02391779, source copy `cardio:ctgov-nct02391779-2018-01-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02391779-2018-01-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Flaxseed Lignan Supplementation in Elderly Participants With Stage I Hypertension
- Condition: Hypertension
- Intervention (Dietary supplement): BeneFlax®
- Intervention (Behavioral): Walking training
- Intervention (Behavioral): Flexibility training
- Intervention (Dietary supplement): Placebo (Whey Protein)
- Intervention (Behavioral): Dash Eating Plan
- Lead sponsor: University of Saskatchewan
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: University of Saskatchewan (`cardio:org-university-of-saskatchewan`)

## Provenance

Content hash: ceba3246c46d0a08aeb5a82636da4dd7b9ae07254c439f51aba22f5c92e7d1e6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
